Irofulven - Lantern Pharma/Oncology Venture US

Drug Profile

Irofulven - Lantern Pharma/Oncology Venture US

Alternative Names: 6-HMAF; 6-hydroxymethylacylfulvene; E 7850; HMAF; Irofulven-1; LP 100; MGI 114

Latest Information Update: 28 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of California, San Diego
  • Developer Dainippon Sumitomo Pharma; Eisai Co Ltd; Lantern Pharma; Oncology Venture
  • Class Antineoplastics; Sesquiterpenes; Small molecules
  • Mechanism of Action Alkylating agents; Apoptosis stimulants; DNA synthesis inhibitors; RNA polymerase II inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer; Renal cell carcinoma; Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Prostate cancer
  • Discontinued Cancer; Liver cancer; Ovarian cancer; Pancreatic cancer; Thyroid cancer

Most Recent Events

  • 26 Jun 2018 2X Oncology is now called Oncology Venture US
  • 31 Jan 2017 Oncology Venture plans to files a Clinical Trial Application in Denmark for Prostate cancer in the second quarter of 2017
  • 17 Jan 2017 Lantern Pharma enters into a strategic collaboration agreement with Cancer Genetics Incorporated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top